NCT00243659View on ClinicalTrials.gov

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Hemophilia A

Interventions

BIOLOGICAL

ReFacto AF

Trial Locations (17)

15213

Pittsburgh

17033

Hershey

22908

Charlottesville

27599

Chapel Hill

48201

Detroit

48202

Detroit

77030

Houston

92093

La Jolla

Unknown

Perth

Vienna

Budapest

Auckland

Chirstchurch

Warsaw

Bucurest

Malmo

Stockholm

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00243659 - Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery | Biotech Hunter | Biotech Hunter